Neurochem says review panel OKs continued phase 3 testing of Alzheimer's drug

By Ted A. Knutson

Washington, Feb. 21 - Neurochem Inc. said Tuesday its Independent Safety Review Board has issued a fourth recommendation to continue the company's North American phase 3 clinical trial for Alzhemed (tramiprosate) for the treatment of Alzheimer's disease.

Neurochem's review board for Alzhemed is made up of independent clinical experts who monitor and evaluate the safety of patients taking part in the Alzhemed trial and who perform related analyses on the safety of those patients.

The recommendation of the board was based on its recent review of the available safety data of all 1,052 patients who have been on study medication for an average of eight months.

Alzhemed is a small, orally administered molecule designed to modify the course of Alzheimer's as an amyloid (beta) antagonist by binding to soluble amyloid (beta) peptide to inhibit or reduce amyloid deposition.

Neurochem is a Laval, Quebec-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.